PMID- 34991832
OWN - NLM
STAT- MEDLINE
DCOM- 20220113
LR  - 20220531
IS  - 2253-8089 (Electronic)
IS  - 2253-8089 (Linking)
VI  - 41
IP  - 1
DP  - 2022 Jan-Feb
TI  - Immunohistochemical expression of VEGFR1 in non small cell lung carcinomas: Lower 
      VEGFR1 expression is asociated with squamous cell carcinoma subtype and high SUV 
      max values in (18)F-FDG PET.
PG  - 28-31
LID - S2253-8089(21)00001-X [pii]
LID - 10.1016/j.remnie.2021.01.001 [doi]
AB  - BACKGROUND: To study the possible relation between immunohistochemical expression 
      of vascular endothelial growth factor receptor 1 (VEGFR1) and the maximum 
      standardised uptake value (SUV max) of (18)F-FDG PET in patients with non small 
      cell lung cancer (NSCLC). MATERIAL AND METHODS: The study included 39 patients 
      with NSCLC (24 squamous cell carcinomas and 15 adenocarcinomas). According to the 
      clinical stage, the patients were distributed as follows: 8 stage I, 7 stage II, 
      15 stage III and 9 stage IV. Immunohistochemical expression of VEGFR1 was studied 
      through the technique of tissue-matrix using Tissue Arrayer Device (Beecher 
      Instruments, Sun Prairie, WI), using the polyclonal antibody against VEGFR1 
      (Santa Cruz Biotechnology, California, USA). RESULTS: Positive VEGFR1 
      immunohistochemical expression was noted in 23 cases (59%). The number of 
      positive tumours was not related with clinical stage but there was a different 
      statistically significant association (p:0,0009) between VEGFR1 positivity and 
      histological type, corresponding the greater percentages of positive results to 
      adenocarcinomas (93,3%) versus in squamous cell carcinomas (37,5%). Likewise, SUV 
      max values were higher (p: 0,039) in negative VEGFR1 carcinomas than in positive 
      VEGFR1 tumors (r: 4-32,1; 16,4+/-6,4 (median 16,1) vs r: 3-47; 14,5+/-8,6 
      (12,8)). CONCLUSIONS: Our results led us to consider that in NSCLC, the negative 
      VEGFR1 immunohistochemical expression is associated significantly with squamous 
      cell carcinomas subtype and with higher SUV max values in (18)F-FDG-PET.
CI  - Copyright (c) 2021 Sociedad Espanola de Medicina Nuclear e Imagen Molecular. 
      Published by Elsevier Espana, S.L.U. All rights reserved.
FAU - Pombo Pasin, M C
AU  - Pombo Pasin MC
AD  - Department of Nuclear Medicine, Complejo Hospitalario Universitario de Santiago 
      de Compostela, Spain. Electronic address: MACarmen.pombo.pasin@sergas.es.
FAU - Pubul Nunez, V
AU  - Pubul Nunez V
AD  - Department of Nuclear Medicine, Complejo Hospitalario Universitario de Santiago 
      de Compostela, Spain.
FAU - Garcia Bernardo, L
AU  - Garcia Bernardo L
AD  - Department of Nuclear Medicine, Complejo Hospitalario Universitario de Santiago 
      de Compostela, Spain.
FAU - Gude Sampedro, F
AU  - Gude Sampedro F
AD  - Clinical Epidemiology Unit, Complejo Hospitalario Universitario de Santiago de 
      Compostela, Spain.
FAU - Abdulkader-Nallib, I
AU  - Abdulkader-Nallib I
AD  - Department of Pathology, Complejo Hospitalario Universitario de Santiago de 
      Compostela. Spain.
FAU - Ruibal Morell, A
AU  - Ruibal Morell A
AD  - Department of Nuclear Medicine, Complejo Hospitalario Universitario de Santiago 
      de Compostela, Spain; Molecular Imaging Group. USC- IDIS. University of Santiago 
      de Compostela, Spain; Fundacion Tejerina. Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20210128
PL  - Spain
TA  - Rev Esp Med Nucl Imagen Mol (Engl Ed)
JT  - Revista espanola de medicina nuclear e imagen molecular
JID - 101770941
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - EC 2.7.10.1 (FLT1 protein, human)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-1)
SB  - IM
MH  - *Carcinoma, Non-Small-Cell Lung/diagnostic imaging
MH  - *Carcinoma, Squamous Cell/diagnostic imaging
MH  - Fluorodeoxyglucose F18
MH  - Humans
MH  - *Lung Neoplasms/diagnostic imaging
MH  - Positron-Emission Tomography
MH  - Radiopharmaceuticals
MH  - Vascular Endothelial Growth Factor Receptor-1/*genetics
OTO - NOTNLM
OT  - SUV max-(18)F-FDG-PET
OT  - SUV max-18F-FDG-PET
OT  - VEGFR1
OT  - carcinomas de celulas no pequenas
OT  - non-small cell carcinomas
EDAT- 2022/01/08 06:00
MHDA- 2022/01/14 06:00
CRDT- 2022/01/07 05:53
PHST- 2020/05/10 00:00 [received]
PHST- 2020/08/05 00:00 [accepted]
PHST- 2022/01/07 05:53 [entrez]
PHST- 2022/01/08 06:00 [pubmed]
PHST- 2022/01/14 06:00 [medline]
AID - S2253-8089(21)00001-X [pii]
AID - 10.1016/j.remnie.2021.01.001 [doi]
PST - ppublish
SO  - Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022 Jan-Feb;41(1):28-31. doi: 
      10.1016/j.remnie.2021.01.001. Epub 2021 Jan 28.